A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65)

NCT06504394 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

66

Enrollment

INDUSTRY

Sponsor class

Conditions

Classical Hodgkin Lymphoma Recurrent
Classical Hodgkin Lymphoma Refractory
Primary Mediastinal Large B-cell Lymphoma Recurrent
Primary Mediastinal Large B-cell Lymphoma Refractory

Interventions

BIOLOGICAL: Pembrolizumab (+) Berahyaluronidase alfa

Sponsor

Merck Sharp & Dohme LLC